Expanded access policy

At Tisento, we are committed to developing therapies that can make a meaningful difference for patients and families affected by serious diseases. Tisento does not currently have an expanded access or compassionate use program. Following the PRIZM study results, which did not demonstrate a treatment benefit, development of zagociguat was discontinued, and the investigational drug is not available through expanded access.